Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
KisqaliⓇ grew 36% in Q2 with share gains ex-US
Sales evolution
USD m, % cc
Ex-US
US
Strength of OS data in aBC is driving differentiation in the class
Updated OS data from MONALEESA-3 presented at ASCO showed prolonged
and consistent OS benefit with a median OS of ~4.5 years1
Only CDK 4/6i to demonstrate OS benefit in 2 Ph3 trials and longest median OS
+36%
225
KisqaliⓇ gaining growth momentum despite slow market recovery
159
142
80
79
Q2 2020
Ex-US: Continued strong double-digit growth, with uptake driven by patient
share gains in Europe; market leader in pre-menopausal setting in France,
Italy and Spain
■ US: Q2 sales +17% vs. Q1, benefitting from higher demand due to increased
field force reach coupled with targeted digital engagement
Potential to become the only CDK4/6i in intermediate and high-risk eBC
NATALEE adjuvant study completed enrollment; readout expected in 2022
83
■
Q2 2021
aBC advanced breast cancer eBC early breast cancer 1. Intent to treat population.
28 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation